Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of P-Anisic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.95 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 5/20 | 0.95 |
| ▸ | CES2 | O00748 | 2/20 | 0.67 |
| ▸ | CES1 | P23141 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | XDH | P47989 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.61 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Anisic Acid SCHEMBL43335 | 0.98 | CA1 (1.00) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL1157044 | 0.98 | CA1 (1.00) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL38654440 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL2130101 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL15347432 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL1043957 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL846287 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL15548197 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL17891327 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 | |
| P-Anisic Acid SCHEMBL29790432 | 0.95 | CA1 (0.95) | CA1CA2CES2CES1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104350047-B | substituted chroman compounds as calcium sensing receptor modulators | 卢平亚特兰蒂斯控股有限公司 | 2017-05-24 | — | — | CN | claimed |
| EP-3689849-B1 | PERFUME PRECURSOR | TAKASAGO PERFUMERY CO LTD (JP) | 2025-01-15 | — | — | EP | disclosed |
| US-11802258-B2 | Perfume precursor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11342511-B2 | Azoline ring-containing compound, electron transport/injection layer material containing the same, and organic electroluminescent element using the same | SK MATERIALS JNC CO., LTD. (KR) | 2022-05-24 | — | — | US | disclosed |
| US-20210214644-A1 | PERFUME PRECURSOR | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3689849-A1 | PERFUME PRECURSOR | Takasago International Corporation (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-20180212156-A1 | AZOLINE RING-CONTAINING COMPOUND, ELECTRON TRANSPORT/INJECTION LAYER MATERIAL CONTAINING THE SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-4255328-A | CEPHALOSPORINS | CIBA-GEIGY CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4234578-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4189486-A | FUNGICIDES | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1980-02-19 | — | — | US | disclosed |
| US-4147864-A | Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4110533-A | PROCESS FOR THE MANUFACTURE OF ENOL DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4073902-A | ANTIMICROBIAL COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3989695-A | 7β-Amino-cepham-3-ol-4-carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
| US-3976591-A | A PHENYL P-METHOXYBENZOATE, A SUBSTITUTED DIPHENYL ACETYLENE | THOMSON-CSF (FR) | 1976-08-24 | — | — | US | disclosed |
| US-3932465-A | ANTIBIOTIC | CIBA-GEIGY CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802258-B2 | Perfume precursor | CYP2E1, ADH1A, CYP1A1 | CA2 3624/4885PARP1 651/4885CA1 3362/4885 |
| US-11342511-B2 | Azoline ring-containing compound, electron transport/injection layer material containing the same, and organic electroluminescent element using the same | SLC7A5, EML4, ARNT | CA2 1008/4885PARP1 4137/4885CA1 2138/4885 |
| US-20210214644-A1 | PERFUME PRECURSOR | CYP2E1, ADH1A, CYP1A1 | CA2 3624/4885PARP1 651/4885CA1 3362/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885PARP1 1237/4885CA1 4818/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885PARP1 1237/4885CA1 4818/4885 |
| US-20180212156-A1 | AZOLINE RING-CONTAINING COMPOUND, ELECTRON TRANSPORT/INJECTION LAYER MATERIAL CONTAINING THE SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SLC7A5, EML4, ARNT | CA2 1008/4885PARP1 4137/4885CA1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.